European Urology Open Science
ISSN / EISSN : 2666-1683 / 2666-1683
Published by: Elsevier BV (10.1016)
Total articles ≅ 2,570
Latest articles in this journal
European Urology Open Science, Volume 33, pp 56-60; https://doi.org/10.1016/j.euros.2021.08.010
We report two cases with recurrences of urachal adenocarcinoma (UrAC) in the urethra. Both patients had mucinous UrAC without metastasis, for which they were treated with en-bloc partial cystectomy and umbilectomy. The first patient developed recurrence of UrAC in the distal urethra after 1 yr. Distal urethrectomy revealed multiple additional recurrences in the penile and prostatic urethra. The patient underwent radical cystoprostatectomy with en-bloc urethrectomy. At 5 mo after surgery, liver metastases were found. A search in our institutional database revealed a second patient who developed a solitary recurrence of UrAC in the prostatic urethra 8 yr after partial cystectomy. Radical cystoprostatectomy was performed. The patient subsequently experienced recurring UrAC in the urethra, which were treated with multiple surgeries and radiation. Unfortunately, local tumor control could not be achieved and the patient developed distant metastases 7 yr after cystoprostatectomy. Our two cases and four comparable cases reported in the literature indicate that urothelial spread of UrAC is rare but possible. It remains to be determined if UrAC spreads along the urothelium similar to urothelial cancer or if these multifocal urethral recurrences were the first sign of local metastasis.
European Urology Open Science, Volume 33, pp 11-18; https://doi.org/10.1016/j.euros.2021.08.007
Considering the relatively high 5-yr survival rate (76.9%) for bladder cancer (BC), its overall prevalence will probably continue to increase. Therefore, it is important to understand the effects of BC diagnosis and management, including psychological sequelae.
European Urology Open Science, Volume 33, pp 19-27; https://doi.org/10.1016/j.euros.2021.09.002
Germ cell tumors represent highly curable disease even in metastatic stage. However, poor-risk patients with an unfavorable serum tumor marker (STM) decline after the first cycle of chemotherapy represent a subgroup with dismal prognosis, with approximately 50% cure rate using bleomycin, etoposide, and cisplatin (BEP).
European Urology Open Science, Volume 33, pp 28-41; https://doi.org/10.1016/j.euros.2021.08.009
Benign prostatic hyperplasia (BPH) associated with lower urinary tract symptoms (LUTS) is diagnosed in up to 80% of men during their lifetime. Several novel ultra-minimally invasive surgical treatments (uMISTs) for BPH/benign prostatic obstruction (BPO) have become available over the past 5 yr.
European Urology Open Science, Volume 33, pp 1-10; https://doi.org/10.1016/j.euros.2021.08.005
Radical cystectomy (RC) is associated with high morbidity.
European Urology Open Science, Volume 31; https://doi.org/10.1016/s2666-1683(21)00188-9
European Urology Open Science, Volume 31; https://doi.org/10.1016/s2666-1683(21)00229-9
European Urology Open Science, Volume 31; https://doi.org/10.1016/s2666-1683(21)00164-6
European Urology Open Science, Volume 31; https://doi.org/10.1016/s2666-1683(21)00192-0
European Urology Open Science, Volume 31; https://doi.org/10.1016/s2666-1683(21)00206-8